RxDoctor Payments Data

Jeffrey Quintana, MD

Pain Medicine · Milwaukee, WINPI 1992885297

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,279 of the $18,747 with a category attached, or 76.2%. It is spread thinly across 38 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.

$18,747in general payments, 2019–2025

Across 382 payments — averaging $49.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Boston Scientific$2K
  • Abbott$2K
  • Medtronic$2K
  • Saluda Medical Americas, Inc.$2K
  • Spinal Simplicity, LLC$1K
  • plus $7K from 32 others

What the payments were for

  • Travel & lodging$4,46824%
  • Food & beverage$14,27976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,747 in reported general payments places this provider in the 85th percentile of 82 pain medicine providers in Wisconsin.

See all pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$124,270
Medicare patients
351
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate18$9,516
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen167$4,550
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,758
Buprenorphine19$2,157
Baclofen22$2,070
Gabapentin160$1,756
Morphine Sulfate ErMorphine Sulfate41$1,278
Pregabalin70$1,141
Lidocaine11$1,065
Tramadol Hcl66$801
Tizanidine Hcl75$703
Morphine Sulfate19$290
Cyclobenzaprine Hcl36$240
Topiramate21$203
Methylprednisolone14$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$775$9,51618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 pain medicine providers in Wisconsin.

Other pain medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →